Low- and Very Low-Dose Bevacizumab for Retinopathy of Prematurity: Reactivations, Additional Treatments, and 12-Month Outcomes
Sharon F Freedman,Amra Hercinovic,David K Wallace,Raymond T Kraker,Zhuokai Li,Amit R Bhatt,Charline S Boente,Eric R Crouch,G Baker Hubbard,David L Rogers,Deborah VanderVeen,Michael B Yang,Nathan L Cheung,Susan A Cotter,Jonathan M Holmes,Pediatric Eye Disease Investigator Group,Sasapin G Prakalapakorn,Sarah K Jones,Navajyoti R Barman,Robert J House,David A Nasrazadani,Eric Crouch,Earl R Crouch Jr,Gaylord G Ventura,Eniolami O Dosunmu,Michael E Gray,William W Motley,Katherine Castleberry,Patricia Cobb,Patricia Hirsch,Melissa Reed,Monica A Sandoval,Neil Vallabh,Don L Bremer,Richard P Golden,Catherine O Jordan,Mary Lou McGregor,Rachel E Reem,Amanda N Schreckengost,Sara A Maletic,Rachel T Miller,David K Coats,Gihan Romany,Ann B Demmy,Lingkun X Kong,Mary E Hartnett,David C Dries,Robert O Hoffman,Susan Allman,Katie J Farnsworth,Barbara Hart,Kelliann Ordonez,Amy K Hutchinson,George B Hubbard 3rd,Prethy Rao,Joshua E Robinson,Judy L Brower,Kathryn M Haider,Heather A Smith,Elizabeth A Hynes,Michele E Whitaker,Deborah K VanderVeen,Jason S Mantagos,Carolyn Wu,Samantha Goldstein,Tamar Winter,Grace X Yoon,R Michael Siatkowski,Janine E Collinge,Kelli J Satnes,Michelle H Blunt,Michael X Repka,Courtney Kraus,Jennifer A Shepard,Roy W Beck,Darrell S Austin,Nicole M Boyle,Danielle L Chandler,Patricia L Connelly,Courtney L Conner,Quayleen Donahue,Brooke P Fimbel,Robert J Henderson,James E Hoepner,Joseph D Kaplon,B Michele Melia,Gillaine Ortiz,Julianne L Robinson,Kathleen M Stutz,Desirae R Sutherland,David O Toro,Victoria C Woodard,Rui Wu,Eileen E Birch,Angela M Chen,Stephen P Christiansen,Eric R Crouch 3rd,Laura B Enyedi,S Ayse Erzurum,Donald F Everett,William V Good,Erin C Jenewein,Katherine A Lee,Richard London,Vivian M Manh,Ruth E Manny,Beth A Morrell,David G Morrison,David B Petersen,Stacy L Pineles,Hantamalala Ralay Ranaivo,Tawna L Roberts,Scott T Ruark,Bonita R Schweinler,Jayne L Silver,Donny W Suh,Allison I Summers,Lisa C Verderber,Katherine K Weise,Marie Diener-West,John D Baker,Barry Davis,Dale L Phelps,Stephen W Poff,Richard A Saunders,Lawrence Tychsen
DOI: https://doi.org/10.1016/j.ophtha.2022.05.019
IF: 14.277
Ophthalmology
Abstract:Purpose: Low-dose and very low-dose intravitreal bevacizumab (IVB) have been reported to be successful in short-term treatment of type 1 retinopathy of prematurity (ROP), down to an initial dose of 0.004 mg. We now report 12-month outcomes for these infants. Design: Masked, multicenter, dose de-escalation study. Participants: One hundred twenty prematurely born infants with type 1 ROP. Methods: A cohort of 120 infants with type 1 ROP in at least 1 eye from 2 sequential dose de-escalation studies of low-dose IVB (0.25 mg, 0.125 mg, 0.063 mg, and 0.031 mg) or very low-dose IVB (0.016 mg, 0.008 mg, 0.004 mg, and 0.002 mg) to the study eye; the fellow eye (if also type 1) received 1 dose level higher of IVB. After primary success or failure at 4 weeks, clinical management was at investigator discretion, including all additional treatment. Main outcome measures: Reactivation of severe ROP by 6 months corrected age, additional treatments, retinal and other ocular structural outcomes, and refractive error at 12 months corrected age. Results: Sixty-two of 113 study eyes (55%) and 55 of 98 fellow eyes (56%) received additional treatment. Of the study eyes, 31 (27%) received additional ROP treatment, and 31 (27%) received prophylactic laser therapy for persistent avascular retina. No trend toward a higher risk of additional ROP treatment related to initial IVB doses was found. However, time to reactivation among study eyes was shorter in eyes that received very low-dose IVB (mean, 76.4 days) than in those that received low-dose IVB (mean, 85.7 days). At 12 months, poor retinal outcomes and anterior segment abnormalities both were uncommon (3% and 5%, respectively), optic atrophy was noted in 10%, median refraction was mildly myopic (-0.31 diopter), and strabismus was present in 29% of infants. Conclusions: Retinal structural outcomes were very good after low- and very low-dose IVB as initial treatment for type 1 ROP, although many eyes received additional treatment. The rate of reactivation of severe ROP was not associated with dose; however, a post hoc data-driven analysis suggested that reactivation was sooner with very low doses.